W12 Pill - white oval, 10mm
Pill with imprint W12 is White, Oval and has been identified as Risperidone 1 mg. It is supplied by West-Ward Pharmaceutical Corporation.
Risperidone is used in the treatment of Autism; Asperger Syndrome; Schizoaffective Disorder; Schizophrenia; Bipolar Disorder and belongs to the drug class atypical antipsychotics. Risk cannot be ruled out during pregnancy. Risperidone 1 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for W12
Risperidone
- Imprint
- W12
- Strength
- 1 mg
- Color
- White
- Size
- 10.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Atypical antipsychotics
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- West-Ward Pharmaceutical Corporation
- National Drug Code (NDC)
- 00143-9763
- Inactive Ingredients
-
corn starch,
lactose monohydrate,
magnesium stearate,
microcrystalline cellulose,
sodium lauryl sulfate,
titanium dioxide,
silicon dioxide,
polyethylene glycol,
polyvinyl alcohol,
magnesium silicate
Note: Inactive ingredients may vary.
Related images for "W12"
More about risperidone
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (714)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: atypical antipsychotics
- Breastfeeding
Patient resources
- Risperidone drug information
- Risperidone injection
- Risperidone (Intramuscular, Subcutaneous) (Advanced Reading)
- Risperidone (Oral) (Advanced Reading)
- Risperidone Tablets
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris, ... +3 more
Professional resources
- Risperidone monograph
- Risperidone (FDA)
- Risperidone Oral Solution (FDA)
- Risperidone Orally Disintegrating (FDA)
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris, Rykindo
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
